These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 32620667)

  • 1. Sorafenib Might Induce Sarcopenia in Patients With Hepatocellular Carcinoma by Inhibiting Carnitine Absorption.
    Amanuma M; Nagai H; Igarashi Y
    Anticancer Res; 2020 Jul; 40(7):4173-4182. PubMed ID: 32620667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Lenvatinib on Skeletal Muscle Volume and Cardiac Function in Patients with Hepatocellular Carcinoma.
    Nagai H; Amanuma M; Mukozu T; Kobayashi K; Nagumo H; Mohri K; Watanabe G; Yoshimine N; Ogino Y; Daido Y; Matsukiyo Y; Matsui T; Wakui N; Momiyama K; Higai K; Matsuda T; Igarashi Y
    Oncology; 2023; 101(10):634-644. PubMed ID: 37364546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sorafenib as first-line therapy in patients with advanced Child-Pugh B hepatocellular carcinoma-a meta-analysis.
    McNamara MG; Slagter AE; Nuttall C; Frizziero M; Pihlak R; Lamarca A; Tariq N; Valle JW; Hubner RA; Knox JJ; Amir E
    Eur J Cancer; 2018 Dec; 105():1-9. PubMed ID: 30384012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis.
    Pinter M; Sieghart W; Graziadei I; Vogel W; Maieron A; Königsberg R; Weissmann A; Kornek G; Plank C; Peck-Radosavljevic M
    Oncologist; 2009 Jan; 14(1):70-6. PubMed ID: 19144684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lower Serum Sodium Levels Are Associated with the Therapeutic Effect of Sorafenib on Hepatocellular Carcinoma.
    Kegasawa T; Sakamori R; Maesaka K; Yamada R; Tahata Y; Urabe A; Kodama T; Hikita H; Imanaka K; Ohkawa K; Hiramatsu N; Oshita M; Yamada Y; Inada M; Yakushijin T; Imai Y; Tatsumi T; Takehara T
    Dig Dis Sci; 2021 May; 66(5):1720-1729. PubMed ID: 32556820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.
    Wörns MA; Weinmann A; Pfingst K; Schulte-Sasse C; Messow CM; Schulze-Bergkamen H; Teufel A; Schuchmann M; Kanzler S; Düber C; Otto G; Galle PR
    J Clin Gastroenterol; 2009; 43(5):489-95. PubMed ID: 19247201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival and tolerance to sorafenib in Child-Pugh B patients with hepatocellular carcinoma: a prospective study.
    Leal CRG; Magalhães C; Barbosa D; Aquino D; Carvalho B; Balbi E; Pacheco L; Perez R; de Tarso Pinto P; Setubal S
    Invest New Drugs; 2018 Oct; 36(5):911-918. PubMed ID: 29948358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions.
    Lee SH; Song IH; Noh R; Kang HY; Kim SB; Ko SY; Lee ES; Kim SH; Lee BS; Kim AN; Chae HB; Kim HS; Lee TH; Kang YW; Lee JD; Lee HY
    BMC Cancer; 2015 Apr; 15():236. PubMed ID: 25885683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of sarcopenia in patients with hepatocellular carcinoma undergoing sorafenib therapy.
    Nishikawa H; Nishijima N; Enomoto H; Sakamoto A; Nasu A; Komekado H; Nishimura T; Kita R; Kimura T; Iijima H; Nishiguchi S; Osaki Y
    Oncol Lett; 2017 Aug; 14(2):1637-1647. PubMed ID: 28789390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
    Abou-Alfa GK; Schwartz L; Ricci S; Amadori D; Santoro A; Figer A; De Greve J; Douillard JY; Lathia C; Schwartz B; Taylor I; Moscovici M; Saltz LB
    J Clin Oncol; 2006 Sep; 24(26):4293-300. PubMed ID: 16908937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes of cytokines in patients with liver cirrhosis and advanced hepatocellular carcinoma treated by sorafenib.
    Nagai H; Kanekawa T; Kobayashi K; Mukozu T; Matsui D; Matsui T; Kanayama M; Wakui N; Momiyama K; Shinohara M; Ishii K; Igarashi Y; Sumino Y
    Cancer Chemother Pharmacol; 2014 Feb; 73(2):223-9. PubMed ID: 24220937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of pre-sarcopenia in sorafenib treatment for advanced hepatocellular carcinoma.
    Takada H; Kurosaki M; Nakanishi H; Takahashi Y; Itakura J; Tsuchiya K; Yasui Y; Tamaki N; Takaura K; Komiyama Y; Higuchi M; Kubota Y; Wang W; Okada M; Enomoto N; Izumi N
    PLoS One; 2018; 13(6):e0198812. PubMed ID: 29912922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levocarnitine Supplementation Suppresses Lenvatinib-Related Sarcopenia in Hepatocellular Carcinoma Patients: Results of a Propensity Score Analysis.
    Okubo H; Ando H; Nakadera E; Ikejima K; Shiina S; Nagahara A
    Nutrients; 2021 Dec; 13(12):. PubMed ID: 34959980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sorafenib treatment by Child-Pugh score in Latin American patients with hepatocellular carcinoma.
    de Guevara LL; Dagher L; Arruda VM; Nakajima K; Kudo M
    Future Oncol; 2020 Nov; 16(31):2511-2520. PubMed ID: 32783460
    [No Abstract]   [Full Text] [Related]  

  • 15. Association between Skeletal Muscle Depletion and Sorafenib Treatment in Male Patients with Hepatocellular Carcinoma: A Retrospective Cohort Study.
    Naganuma A; Hoshino T; Suzuki Y; Uehara D; Kudo T; Ishihara H; Sato K; Kakizaki S; Yamada M; Takagi H
    Acta Med Okayama; 2017 Aug; 71(4):291-299. PubMed ID: 28824184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre-sarcopenia determines post-progression outcomes in advanced hepatocellular carcinoma after sorafenib failure.
    Cheng TY; Lee PC; Chen YT; Chao Y; Hou MC; Huang YH
    Sci Rep; 2020 Oct; 10(1):18375. PubMed ID: 33110117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Therapeutic decisions in the treatment of hepatocellular carcinoma and patterns of sorafenib use. Results of the international observational GIDEON trial in Spain].
    Turnes J; Díaz R; Hernandez-Guerra M; Gómez M; Castells L; Bustamante J; Espinosa MD; Fernández-Castroagudín J; Serrano T; Rendón P; Andrade R; Salgado M; Arenas J; Vergara M; Sala M; Polo BA; Granizo IM; Gonzálvez ML; Viudez A
    Gastroenterol Hepatol; 2015 Apr; 38(4):263-73. PubMed ID: 25583146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baseline Sarcopenia is Associated with Lack of Response to Therapy, Liver Decompensation and High Mortality in Hepatocellular Carcinoma Patients.
    Badran H; Elsabaawy MM; Ragab A; Aly RA; Alsebaey A; Sabry A
    Asian Pac J Cancer Prev; 2020 Nov; 21(11):3285-3290. PubMed ID: 33247686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Skeletal muscle depletion predicts the prognosis of patients with hepatocellular carcinoma treated with sorafenib.
    Imai K; Takai K; Hanai T; Ideta T; Miyazaki T; Kochi T; Suetsugu A; Shiraki M; Shimizu M
    Int J Mol Sci; 2015 Apr; 16(5):9612-24. PubMed ID: 25927582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.
    Cho JY; Paik YH; Lim HY; Kim YG; Lim HK; Min YW; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
    Liver Int; 2013 Jul; 33(6):950-7. PubMed ID: 23601249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.